# A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

> **NCT02538536** · PHASE2 · COMPLETED · sponsor: **Liminal BioSciences Ltd.** · enrollment: 41 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis (IPF)

## Interventions

- **DRUG:** PBI4050

## Key facts

- **NCT ID:** NCT02538536
- **Lead sponsor:** Liminal BioSciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2017-01
- **Final completion:** 2017-01
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02538536

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02538536, "A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02538536. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*